Sanofi vaccines division, Sanofi Pasteur, has begun shipping of the first lots of Fluzone vaccine to US health care providers following Food and Drug Administration (FDA) licensure of the 2012-2013 formulation.
The shipment represents more than 60 million doses of seasonal influenza vaccine the company plans to deliver to health care providers in the US this influenza season.
Sanofi Pasteur US chief commercial officer Chad Hoover said this year, two new virus strains were recommended for the seasonal influenza vaccine formulation.
"As the supplier of nearly half of the nation's influenza vaccine, it was a critical challenge for us to be early to market so that health care providers had confidence in their supply of influenza vaccine," Hoover added.
Sanofi Pasteur also announced that its syringe presentations of Fluzone and Fluzone High-Dose vaccines have a new syringe cap that does not contain latex.
Sanofi Pasteur will make available Fluzone, Fluzone High-Dose and Fluzone Intradermal vaccines to cater to the immunisation needs of each age group.
"With these influenza vaccine options, our goal is to help improve the immunization experience for patients and their health care providers thus helping to improve immunization rates" Hoover further added.
